STOCK TITAN

PTC Therapeutics (PTCT) CTO exercises options and sells stock under plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics, Inc. chief technical operations officer Neil Gregory Almstead reported a series of option exercises and share sales in PTCT common stock. On June 24–25, 2026, he exercised stock options for a total of 26,283 shares at exercise prices including $38.10 and $39.42 per share.

Over the same two days, he sold 26,283 shares of common stock in open-market transactions at prices generally in the mid‑$80s, with individual sale prices such as $87.00 and weighted‑average prices around $85–$86 per share. Following these transactions, Almstead directly holds 60,137 shares of PTCT common stock.

The filing notes that these transactions were carried out under a written Rule 10b5-1 trading plan adopted on November 11, 2025, indicating they were pre‑scheduled rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider Almstead Neil Gregory
Role CHIEF TECHNICAL OPS OFFICER
Sold 26,283 shs ($2.25M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 1,001 $0.00 --
Exercise Stock Option (Right to Buy) 19,859 $0.00 --
Exercise Stock Option (Right to Buy) 100 $0.00 --
Exercise Common Stock 1,001 $38.10 $38K
Sale Common Stock 582 $85.24 $50K
Sale Common Stock 419 $86.39 $36K
Exercise Common Stock 19,859 $38.10 $757K
Sale Common Stock 8,522 $85.26 $727K
Sale Common Stock 11,337 $86.51 $981K
Exercise Common Stock 100 $39.42 $4K
Sale Common Stock 100 $87.00 $9K
Exercise Stock Option (Right to Buy) 401 $0.00 --
Exercise Stock Option (Right to Buy) 4,922 $0.00 --
Exercise Common Stock 401 $38.10 $15K
Sale Common Stock 401 $85.01 $34K
Exercise Common Stock 4,922 $38.10 $188K
Sale Common Stock 4,922 $85.03 $419K
Holdings After Transaction: Stock Option (Right to Buy) — 47,676 shares (Direct, null); Common Stock — 61,138 shares (Direct, null)
Footnotes (1)
  1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.84 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.23 to $86.59 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.02 to $86.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Shares sold 26,283 shares Total common shares sold in open-market transactions on June 24–25, 2026
Shares acquired via option exercise 26,283 shares Total common shares acquired through option exercises on June 24–25, 2026
Common shares held after transactions 60,137 shares Direct PTCT common stock ownership following reported trades
Highest reported sale price $87.00 per share Open-market sale price for 100 PTCT shares on June 25, 2026
Option exercise price $39.42 per share Exercise price for 100 stock options converted to common stock
Option exercise price $38.10 per share Exercise price for multiple stock option tranches converted to common stock
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
weighted average price financial
"This price represents the weighted average price of sale transactions that were executed in multiple trades"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Almstead Neil Gregory

(Last)(First)(Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE

(Street)
WARREN NEW JERSEY 07059

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF TECHNICAL OPS OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/24/2026M(1)401A$38.160,538D
Common Stock06/24/2026S(1)401D$85.01(2)60,137D
Common Stock06/24/2026M(1)4,922A$38.165,059D
Common Stock06/24/2026S(1)4,922D$85.03(3)60,137D
Common Stock06/25/2026M(1)1,001A$38.161,138D
Common Stock06/25/2026S(1)582D$85.24(4)60,556D
Common Stock06/25/2026S(1)419D$86.39(5)60,137D
Common Stock06/25/2026M(1)19,859A$38.179,996D
Common Stock06/25/2026S(1)8,522D$85.26(6)71,474D
Common Stock06/25/2026S(1)11,337D$86.51(7)60,137D
Common Stock06/25/2026M(1)100A$39.4260,237D
Common Stock06/25/2026S(1)100D$8760,137D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$38.106/24/2026M(1)401 (8)01/06/2032Common Stock401$053,599D
Stock Option (Right to Buy)$38.106/24/2026M(1)4,922 (8)01/06/2032Common Stock4,922$048,677D
Stock Option (Right to Buy)$38.106/25/2026M(1)1,001 (8)01/06/2032Common Stock1,001$047,676D
Stock Option (Right to Buy)$38.106/25/2026M(1)19,859 (8)01/06/2032Common Stock19,859$027,817D
Stock Option (Right to Buy)$39.4206/25/2026M(1)100 (9)01/04/2033Common Stock100$036,150D
Explanation of Responses:
1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.84 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.23 to $86.59 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
7. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.02 to $86.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
8. Currently exercisable.
9. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
/s/ Avraham S. Adler, Attorney-in-Fact06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PTCT executive Neil Gregory Almstead report?

Neil Gregory Almstead reported exercising stock options for 26,283 PTCT shares and selling 26,283 common shares in open-market trades. These combined transactions occurred on June 24–25, 2026 and were conducted under a pre-established Rule 10b5-1 trading plan.

How many PTC Therapeutics (PTCT) shares does Neil Gregory Almstead hold after these trades?

After the reported June 2026 transactions, Neil Gregory Almstead directly holds 60,137 shares of PTC Therapeutics common stock. This figure reflects both the exercised stock options and the shares sold, as disclosed in the Form 4 insider transaction summary.

At what prices did Neil Gregory Almstead sell PTCT shares in June 2026?

Almstead’s reported PTCT share sales were executed mainly in the mid-$80s per share, including specific reported prices such as $87.00, $86.51 and $85.03. Several trades used weighted-average sale prices across ranges near $85–$86 per share.

What option exercise prices did PTCT’s Neil Gregory Almstead disclose in his Form 4?

The Form 4 shows Almstead exercising stock options to acquire PTCT common shares at exercise prices including $38.10 and $39.42 per share. These derivative exercises converted previously granted options into common stock before subsequent open-market sales.

Were Neil Gregory Almstead’s PTCT stock sales made under a Rule 10b5-1 plan?

Yes. A footnote explains that the reported transactions were effected under a written Rule 10b5-1 trading plan adopted on November 11, 2025. Such pre-arranged plans schedule trades in advance to reduce concerns about discretionary market timing.